<!DOCTYPE html> <html lang="en"> <head> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"> <meta charset="utf-8"> <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <title> Jim M. Smit </title> <meta name="author" content="Jim M. Smit"> <meta name="description" content="A simple, whitespace theme for academics. Based on [*folio](https://github.com/bogoli/-folio) design. "> <meta name="keywords" content="jekyll, jekyll-theme, academic-website, portfolio-website"> <link rel="stylesheet" href="/assets/css/bootstrap.min.css?a4b3f509e79c54a512b890d73235ef04"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/mdbootstrap@4.20.0/css/mdb.min.css" integrity="sha256-jpjYvU3G3N6nrrBwXJoVEYI/0zw8htfFnhT9ljN3JJw=" crossorigin="anonymous"> <link defer rel="stylesheet" href="/assets/css/academicons.min.css?f0b7046b84e425c55f3463ac249818f5"> <link defer rel="stylesheet" href="/assets/css/scholar-icons.css?62b2ac103a88034e6882a5be5f3e2772"> <link defer rel="stylesheet" type="text/css" href="https://fonts.googleapis.com/css?family=Roboto:300,400,500,700|Roboto+Slab:100,300,400,500,700|Material+Icons&amp;display=swap"> <link defer rel="stylesheet" href="/assets/css/jekyll-pygments-themes-github.css?591dab5a4e56573bf4ef7fd332894c99" media="" id="highlight_theme_light"> <link rel="shortcut icon" href="data:image/svg+xml,&lt;svg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20100%20100%22&gt;&lt;text%20y=%22.9em%22%20font-size=%2290%22&gt;%F0%9F%9A%80&lt;/text&gt;&lt;/svg&gt;"> <link rel="stylesheet" href="/assets/css/main.css?d41d8cd98f00b204e9800998ecf8427e"> <link rel="canonical" href="https://jimmsmit.github.io/"> <script src="/assets/js/theme.js?9a0c749ec5240d9cda97bc72359a72c0"></script> <link defer rel="stylesheet" href="/assets/css/jekyll-pygments-themes-native.css?5847e5ed4a4568527aa6cfab446049ca" media="none" id="highlight_theme_dark"> <script>
    initTheme();
  </script> </head> <body class="fixed-top-nav "> <header> <nav id="navbar" class="navbar navbar-light navbar-expand-sm fixed-top" role="navigation"> <div class="container"> <button class="navbar-toggler collapsed ml-auto" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar top-bar"></span> <span class="icon-bar middle-bar"></span> <span class="icon-bar bottom-bar"></span> </button> <div class="collapse navbar-collapse text-right" id="navbarNav"> <ul class="navbar-nav ml-auto flex-nowrap"> <li class="nav-item active"> <a class="nav-link" href="/">about <span class="sr-only">(current)</span> </a> </li> <li class="nav-item "> <a class="nav-link" href="/publications/">publications </a> </li> <li class="nav-item "> <a class="nav-link" href="/cv/">cv </a> </li> <li class="nav-item"> <button id="search-toggle" title="Search" onclick="openSearchModal()"> <span class="nav-link">ctrl k <i class="ti ti-search"></i></span> </button> </li> <li class="toggle-container"> <button id="light-toggle" title="Change theme"> <i class="ti ti-sun-moon" id="light-toggle-system"></i> <i class="ti ti-moon-filled" id="light-toggle-dark"></i> <i class="ti ti-sun-filled" id="light-toggle-light"></i> </button> </li> </ul> </div> </div> </nav> <progress id="progress" value="0"> <div class="progress-container"> <span class="progress-bar"></span> </div> </progress> </header> <div class="container mt-5" role="main"> <div class="post"> <header class="post-header"> <h1 class="post-title"> <span class="font-weight-bold">Jim</span> M. Smit </h1> <p class="desc">Intensive Care Medicine | Causal Inference | Machine Learning</p> </header> <article> <div class="profile float-right"> <figure> <picture> <source class="responsive-img-srcset" srcset="/assets/img/prof_pic-480.webp 480w,/assets/img/prof_pic-800.webp 800w,/assets/img/prof_pic-1400.webp 1400w," type="image/webp" sizes="(min-width: 930px) 270.0px, (min-width: 576px) 30vw, 95vw"> <img src="/assets/img/prof_pic.jpg?3545b75b551d5715fee057879425166a" class="img-fluid z-depth-1 rounded" width="100%" height="auto" alt="prof_pic.jpg" loading="eager" onerror="this.onerror=null; $('.responsive-img-srcset').remove();"> </source></picture> </figure> <div class="more-info"> <p>Intensive Care Department</p> <p>Erasmus Medical Center</p> <p>Pattern Recognition &amp; Bioinformatics</p> <p>Delft University of Technology</p> <p>Rotterdam / Delft, Netherlands</p> </div> </div> <div class="clearfix"> <p>PhD Candidate at the Intensive Care department and <a href="https://datahub.health/" rel="external nofollow noopener" target="_blank">Datahub</a> of the Erasmus Medical Center, Rotterdam, collaborating with the <a href="https://www.tudelft.nl/ewi/over-de-faculteit/afdelingen/intelligent-systems/pattern-recognition-bioinformatics/pattern-recognition-bioinformatics/people" rel="external nofollow noopener" target="_blank">Pattern Recognition &amp; Bioinformatics group</a> of Delft University of Technology. Focusing on Machine Learning /Artificial Intelligence applications to improve Healthcare, with a special interest in Causal Inference.</p> <p>Find me on <a href="https://x.com/JimSmit_" rel="external nofollow noopener" target="_blank">X/Twitter</a>, <a href="https://www.linkedin.com/in/jim-smit-58ab7413b/" rel="external nofollow noopener" target="_blank">LinkedIn</a>, and <a href="https://scholar.google.com/citations?hl=en&amp;user=vYRPFsEAAAAJ&amp;view_op=list_works&amp;sortby=pubdate" rel="external nofollow noopener" target="_blank">Google Scholar</a>.</p> </div> <h2> <a href="/news/" style="color: inherit">news</a> </h2> <div class="news"> <div class="table-responsive"> <table class="table table-sm table-borderless"> <tr> <th scope="row" style="width: 20%">Jan 29, 2025</th> <td> üì¢ New Publication! üì¢<br> <br> Our data-driven analysis of randomised trials to predict benefit from corticosteroids in hopitalised Community-Acquired-Pneumonia (CAP) is now available in the latest issue of Lancet Respiratory Medicine<br> <br> Here are the key take-aways:<br> <br> üí° The Controversy: <ul> <li>Routine corticosteroid use for CAP is debated, with conflicting recommendations in recent SCCM and ERS / ESICM ESCMID / ALAT guidelines.</li> <li>While some guidelines suggest corticosteroids for severe CAP, evidence remains insufficient and the definition of ‚Äúsevere‚Äù inconsistent</li> </ul> üîç What We Did: <ul> <li>Conducted an individual patient data meta-analysis, covering 8 RCTs and 3,248 patients hospitalised with CAP.</li> <li>Focused on analysing heterogeneity of treatment effects (HTE) using data-driven approaches</li> <li>We developed and externally validated a novel corticosteroid-effect model, pinpointing baseline C-reactive protein (CRP) as a critical predictor for benefit</li> </ul> üìä Key Findings: <ul> <li>We found significant overall mortality reduction from corticosteroids in hospitalized CAP, but ...</li> <li>Survival benefits were tied to high baseline CRP concentrations (&gt;204 mg/L), while patients with lower CRP concentrations showed no mortality benefit.</li> <li>Contrary to earlier assumptions, we found no significant HTE between less severe vs severe CAP (PSI class I‚ÄìIII vs IV‚ÄìV).</li> <li>Trade-offs: Overall increased hospital re-admissions and hyperglycaemia incidence due to corticosteroid use.</li> </ul> üß† Implications for Practice: <ul> <li>Current guidelines overlook CRP levels in corticosteroid treatment decisions.h</li> <li>Our study paves the way for more targeted corticosteroid therapy in CAP, through threshold-based CRP guidance</li> </ul> ‚ú®‚ú®‚ú® Proud of our team of authors, including contributors from seven countries, over ten cities, and a diverse range of both clinical and technical expertise: </td> </tr> <tr> <th scope="row" style="width: 20%">Jan 26, 2025</th> <td> üì¢ New Preprint on medrXiv! üì¢<br> <br> On the Heterogeneous Treatnent Effect of higher vs lower PEEP strategies in ARDS. </td> </tr> </table> </div> </div> <h2> <a href="/publications/" style="color: inherit">selected publications</a> </h2> <div class="publications"> <ol class="bibliography"> <li> <div class="row"> <div class="col col-sm-2 abbr"> </div> <div id="hte_cap" class="col-sm-8"> <div class="title">Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials</div> <div class="author"> Jim M Smit,¬†Philip A Van Der Zee,¬†Sara C M Stoof,¬†Michel E Van Genderen, and <span class="more-authors" title="click to view 32 more authors" onclick=" var element=$(this); element.attr('title', ''); var more_authors_text=element.text() == '32 more authors' ? 'Dominic Snijders, Wim G Boersma, Paola Confalonieri, Francesco Salton, Marco Confalonieri, Mei-Chiung Shih, Gianfranco U Meduri, Pierre-Fran√ßois Dequin, Am√©lie Le Gouge, Melanie Lloyd, Harin Karunajeewa, Grzegorz Bartminski, Silvia Fern√°ndez-Serrano, Guillermo Su√°rez-Cuart√≠n, David Klaveren, Matthias Briel, Christof M Sch√∂nenberger, Ewout W Steyerberg, Diederik A M P J Gommers, Hannelore I Bax, Wilem Jan W Bos, Ewoudt M W Garde, Esther Wittermans, Jan C Grutters, Claudine A Blum, Mirjam Christ-Crain, Antoni Torres, Ana Motos, Marcel J T Reinders, Jasper Van Bommel, Jesse H Krijthe, Henrik Endeman' : '32 more authors'; var cursorPosition=0; var textAdder=setInterval(function(){ element.html(more_authors_text.substring(0, cursorPosition + 1)); if (++cursorPosition == more_authors_text.length){ clearInterval(textAdder); } }, '5'); ">32 more authors</span> </div> <div class="periodical"> <em>The Lancet Respiratory Medicine</em>, 2025 </div> <div class="periodical"> </div> <div class="links"> <a class="abstract btn btn-sm z-depth-0" role="button">Abs</a> <a href="https://doi.org/https://doi.org/10.1016/S2213-2600(24)00405-3" class="btn btn-sm z-depth-0" role="button" rel="external nofollow noopener" target="_blank">DOI</a> </div> <div class="abstract hidden"> <p>Summary Background Despite several randomised controlled trials (RCTs) on the use of adjuvant treatment with corticosteroids in patients with community-acquired pneumonia (CAP), the effect of this intervention on mortality remains controversial. We aimed to evaluate heterogeneity of treatment effect (HTE) of adjuvant treatment with corticosteroids on 30-day mortality in patients with CAP. Methods In this individual patient data meta-analysis, we included RCTs published before July 1, 2024, comparing adjuvant treatment with corticosteroids versus placebo in patients hospitalised with CAP. The primary endpoint was 30-day all-cause mortality, collected across all trials, and analyses followed the intention-to-treat principle. We analysed HTE using risk and effect modelling. For risk modelling, patients were classified as having less severe or severe CAP based on the pneumonia severity index (PSI), comparing PSI class I‚ÄìIII versus class IV‚ÄìV. For effect modelling, we trained a corticosteroid-effect model on six trials and externally validated it using data from two trials, received after model preregistration. This model classified patients into two groups: no predicted benefit and predicted benefit from adjuvant treatment with corticosteroids. The literature search was registered on PROSPERO, CRD42022380746. Findings We included eight RCTs with 3224 patients. Across all eight trials, 246 (7\textperiodcentered6%) patients died within 30 days (106 [6\textperiodcentered6%] of 1618 in the corticosteroid group vs 140 [8\textperiodcentered7%] of 1606 in the placebo group; odds ratio [OR] 0\textperiodcentered72 [95% CI 0\textperiodcentered56‚Äì0\textperiodcentered94], p=0\textperiodcentered017). The corticosteroid-effect model, which selected C-reactive protein (CRP), showed significant HTE during external validation in the two most recent trials. In these trials, 154 (11\textperiodcentered4%) of 1355 patients died within 30 days (88 [13\textperiodcentered1%] of 671 in the placebo group vs 66 [9\textperiodcentered6%] of 684 in the corticosteroid group; OR 0\textperiodcentered71 [95% CI 0\textperiodcentered50‚Äì0\textperiodcentered99], p=0\textperiodcentered044). Among patients predicted to have no benefit (CRP ‚â§204 mg/L, n=725), no significant effect was observed (OR 0\textperiodcentered98 [95% CI 0\textperiodcentered63‚Äì1\textperiodcentered50]), whereas for those with predicted benefit (CRP &gt;204 mg/L, n=630), 39 (13\textperiodcentered0%) of 301 patients died in the placebo group compared with 20 (6\textperiodcentered1%) of 329 in the corticosteroid group (0\textperiodcentered43 [0\textperiodcentered25‚Äì0\textperiodcentered76], pinteraction=0\textperiodcentered026). No significant HTE was found between less severe CAP (PSI class I‚ÄìIII, n=229) and severe CAP (PSI class IV‚ÄìV, n=1126). Corticosteroid therapy significantly increased hyperglycaemia risk (44 [12\textperiodcentered8%] of 344 in the placebo group vs 84 [24\textperiodcentered8%] of 339 in the corticosteroid group; OR 2\textperiodcentered50 [95% CI 1\textperiodcentered63‚Äì3\textperiodcentered83], p&lt;0\textperiodcentered0001) and hospital re-admission risk (30 [3\textperiodcentered7%] of 814 in the placebo group vs 57 [7\textperiodcentered0%] of 819 in the corticosteroid group; 1\textperiodcentered95 [1\textperiodcentered24‚Äì3\textperiodcentered07], p=0\textperiodcentered0038). Interpretation Overall, adjuvant therapy with corticosteroids significantly reduces 30-day mortality in patients hospitalised with CAP. The treatment effect varied significantly among subgroups based on CRP concentrations, with a substantial mortality reduction observed only in patients with high baseline CRP. Funding None.</p> </div> </div> </div> </li> <li> <div class="row"> <div class="col col-sm-2 abbr"> </div> <div id="hte_peep" class="col-sm-8"> <div class="title">The Heterogeneous Effect of High PEEP strategies on Survival in Acute Respiratory Distress Syndrome: preliminary results of a data-driven analysis of randomized trials</div> <div class="author"> Jim M Smit,¬†Jesse H Krijthe,¬†Jasper Bommel,¬†Demet S Sulemanji, and <span class="more-authors" title="click to view 24 more authors" onclick=" var element=$(this); element.attr('title', ''); var more_authors_text=element.text() == '24 more authors' ? 'Jesus Villar, Fernando Suarez-Sipmann, Rosa L Fernandez, Fernando G Zampieri, Israel S Maia, Alexandre B Cavalcanti, Matthias Briel, Maureen O Meade, Qi Zhou, Roy B Brower, Pratik Sinha, Brian Bartek, Carolyn S Calfee, Alain Mercat, Jean-Christophe Richard, Laurent Brochard, Ary Serpa Neto, Carol Hodgson, Elias N Baedorf-Kassis, Daniel Talmor, Diederik Gommers, Michel E Genderen, Marcel J T Reinders, Annemijn H Jonkman' : '24 more authors'; var cursorPosition=0; var textAdder=setInterval(function(){ element.html(more_authors_text.substring(0, cursorPosition + 1)); if (++cursorPosition == more_authors_text.length){ clearInterval(textAdder); } }, '5'); ">24 more authors</span> </div> <div class="periodical"> <em>medRxiv</em>, Jan 2025 </div> <div class="periodical"> </div> <div class="links"> <a class="abstract btn btn-sm z-depth-0" role="button">Abs</a> <a href="https://doi.org/10.1101/2025.01.23.25320649" class="btn btn-sm z-depth-0" role="button" rel="external nofollow noopener" target="_blank">DOI</a> </div> <div class="abstract hidden"> <p>Background: Mixed trial results suggest that some ventilated patients with acute respiratory distress syndrome (ARDS) benefit from high PEEP while others may be harmed, indicating heterogeneity of treatment effect (HTE). This study applies data-driven predictive approaches to uncover HTE and re-examines previously hypothesized HTE. This manuscript serves as a pre-registration of planned external validation of our trained models. Methods: We identified eight randomized trials, and obtained individual patient data (IPD) from three of them (ALVEOLI, LOVS, EXPRESS), as our train cohort. We used effect modelling to predict individualized treatment effects (predicted 28-day mortality risk difference between PEEP strategies) across patient subgroups stratified by observed tertiles (&lt;=8 cmH2O, 9-11 cmH2O, &gt;=12 cmH2O). Candidate effect modelling methods included meta-learners and technique-specific methods. Optimal methods were selected through 'leave-one-trial-out' cross-validation, evaluating the methods' performances in each PEEP tertile using AUC-benefit. We trained final models using the best performing methods implemented with or without forward selection (which yielded sufficient AUC-benefit), and additional final models by selecting the variables that yielded consistency in the forward selections performed in the cross validation, if any. We further evaluated earlier hypothesized HTE comparing (1) patients with baseline PaO2/FiO2 &lt;=200 versus &gt;200 mmHg, and (2) patients with hypoinflammatory versus hyperinflammatory subphenotypes. Preliminary findings: In the lower PEEP tertile (&lt;=8 cmH2O), an X-learner implemented without, and an S-learner implemented with forward selection (both with flexible base learners), yielded the highest AUC benefits and were used to train final models. In the high PEEP tertile (&gt;=12 cmH2O), only the causal forest implemented with forward selection yielded an AUC benefit exceeding zero. Respiratory-system compliance (CRS) was consistently selected in the forward selections of cross validation, and was used to train an extra final causal forest model, with predicted effects shifting from harm to benefit for CRS 26.5 mL/cmH2O or higher. Higher PEEP benefited patients with baseline PaO2/FiO2 &lt;=200 mmHg (OR 0.80, 95% CI 0.66-0.98), incurred harm among those with PaO2;/FiO2 &gt;200 mmHg (OR 1.74, 95% CI 1.02-2.98; interaction P=0.01). This HTE was strongest when PaO2/FiO2 was measured at low PEEP (&lt;=8 cmH2O), reduced at mid-level PEEP (9-11 cmH2O), and negligible at high PEEP (&gt;=12 cmH2O). A second-order interaction showed significant heterogeneity of HTE (ie, second-order heterogeneity) across PEEP tertiles (P=0.03). Preliminary Conclusions: Our preliminary findings indicated that baseline CRS &gt;=26.5 mL/cmH2O predicts benefit, while CRS &lt;26.5 mL/cmH2O predicts harm from high PEEP when CRS is measured at high baseline PEEP (&gt;=12 cmH2O). Similarly, baseline PaO2/FiO2; &lt;=200 mmHg predicts benefit, while PaO2/FiO2 &gt;200 mmHg predicts harm from high PEEP when PaO2/FiO2 is measured at a low baseline PEEP (&lt;=8 cmH2O). Using data from the LOVS trial, we investigated HTE for high PEEP between hypo- and hyperinflammatory subphenotypes but found none, despite significant HTE observed earlier in the ALVEOLI trial.Competing Interest StatementA.H. Jonkman declares research funding paid to the institution by Pulmotech B.V., for validation of new esophageal pressure sensor. D. Talmor declares support from the National Institutes of Health and lecture honoraria from Mindray. J. Villar was funded by Instituto de Salud Carlos III, Madrid, Sapin (CB06/06/1088, PI19/00141, AC-21_2/00039), ERAPerMed(JTC_2021), ERAPerMed(JTC_2021), The European Regional Development Funds, Fundacion Canaria Intituto de Investigacipn Sanitaria de Canarias, and Asociacion Cientifica Pulmon y Ventilacion Mecanica. C.S. Calfee declares grants from NIH, Roche Genentech, and Quantum Leap Healthcare Collaborative to her institution, consulting fees from Vasomune, Gen1e Life Sciences, NGM Bio, Cellenkos, Calcimedica, Arrowhead, EnliTISA, Novartis, and Merck, being speaker at a symposium on ESICM guidelines supported by Fisher-Paykel, a Patent on metagenomic sequencing for sepsis diagnosis (co-recipient) issued to Regents of University of California and Chan Zuckerberg BioHub, and being council member of the International Sepsis Forum (unpaid). Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study included individual patient data from three randomized controlled trials. The trial by Mercat et al. enrolled patinets at 37 intensive care units in France, and their study protocol was approved for all centers by the ethics committee of the Angers University Hospital (Comite Consultatif de Protection des Personnes dans la Recherche Biomedicale), according to French law. The trial by Brower et al. enrolled patients at 23 hospitals of the National HeartLung, and Blood Institute (NHLBI) ARDS Clinical Trials Network, and was approved by the institutional review board of each hospital. The trial by Meade et al. enrolled patients in 30 hospitals in Canada, Australia, and Saudi Arabia, and the research ethics board of each hospital approved the trial.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors</p> </div> </div> </div> </li> </ol> </div> <div class="social"> <div class="contact-icons"> <a href="mailto:%6A.%73%6D%69%74@%65%72%61%73%6D%75%73%6D%63.%6E%6C" title="email"><i class="fa-solid fa-envelope"></i></a> <a href="https://github.com/jimmsmit" title="GitHub" rel="external nofollow noopener" target="_blank"><i class="fa-brands fa-github"></i></a> <a href="https://www.linkedin.com/in/jim-smit-58ab7413b" title="LinkedIn" rel="external nofollow noopener" target="_blank"><i class="fa-brands fa-linkedin"></i></a> <a href="/feed.xml" title="RSS Feed"><i class="fa-solid fa-square-rss"></i></a> <a href="https://scholar.google.com/citations?user=vYRPFsEAAAAJ" title="Google Scholar" rel="external nofollow noopener" target="_blank"><i class="ai ai-google-scholar"></i></a> <a href="https://twitter.com/JimSmit_" title="X" rel="external nofollow noopener" target="_blank"><i class="fa-brands fa-x-twitter"></i></a> </div> <div class="contact-note">Contact me via j.smit@erasmusmc.nl </div> </div> </article> </div> </div> <footer class="fixed-bottom" role="contentinfo"> <div class="container mt-0"> ¬© Copyright 2025 Jim M. Smit. Powered by <a href="https://jekyllrb.com/" target="_blank" rel="external nofollow noopener">Jekyll</a> with <a href="https://github.com/alshedivat/al-folio" rel="external nofollow noopener" target="_blank">al-folio</a> theme. Hosted by <a href="https://pages.github.com/" target="_blank" rel="external nofollow noopener">GitHub Pages</a>. Photos from <a href="https://unsplash.com" target="_blank" rel="external nofollow noopener">Unsplash</a>. </div> </footer> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.0/dist/jquery.min.js" integrity="sha256-/xUj+3OJU5yExlq6GSYGSHk7tPXikynS7ogEvDej/m4=" crossorigin="anonymous"></script> <script src="/assets/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/mdbootstrap@4.20.0/js/mdb.min.js" integrity="sha256-NdbiivsvWt7VYCt6hYNT3h/th9vSTL4EDWeGs5SN3DA=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/masonry-layout@4.2.2/dist/masonry.pkgd.min.js" integrity="sha256-Nn1q/fx0H7SNLZMQ5Hw5JLaTRZp0yILA/FRexe19VdI=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/imagesloaded@5.0.0/imagesloaded.pkgd.min.js" integrity="sha256-htrLFfZJ6v5udOG+3kNLINIKh2gvoKqwEhHYfTTMICc=" crossorigin="anonymous"></script> <script defer src="/assets/js/masonry.js?a0db7e5d5c70cc3252b3138b0c91dcaf" type="text/javascript"></script> <script defer src="https://cdn.jsdelivr.net/npm/medium-zoom@1.1.0/dist/medium-zoom.min.js" integrity="sha256-ZgMyDAIYDYGxbcpJcfUnYwNevG/xi9OHKaR/8GK+jWc=" crossorigin="anonymous"></script> <script defer src="/assets/js/zoom.js?85ddb88934d28b74e78031fd54cf8308"></script> <script src="/assets/js/no_defer.js?2781658a0a2b13ed609542042a859126"></script> <script defer src="/assets/js/common.js?e0514a05c5c95ac1a93a8dfd5249b92e"></script> <script defer src="/assets/js/copy_code.js?12775fdf7f95e901d7119054556e495f" type="text/javascript"></script> <script defer src="/assets/js/jupyter_new_tab.js?d9f17b6adc2311cbabd747f4538bb15f"></script> <script async src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script async src="https://badge.dimensions.ai/badge.js"></script> <script defer type="text/javascript" id="MathJax-script" src="https://cdn.jsdelivr.net/npm/mathjax@3.2.2/es5/tex-mml-chtml.js" integrity="sha256-MASABpB4tYktI2Oitl4t+78w/lyA+D7b/s9GEP0JOGI=" crossorigin="anonymous"></script> <script src="/assets/js/mathjax-setup.js?a5bb4e6a542c546dd929b24b8b236dfd"></script> <script defer src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" crossorigin="anonymous"></script> <script defer src="/assets/js/progress-bar.js?2f30e0e6801ea8f5036fa66e1ab0a71a" type="text/javascript"></script> <script src="/assets/js/vanilla-back-to-top.min.js?f40d453793ff4f64e238e420181a1d17"></script> <script>
    addBackToTop();
  </script> <script type="module" src="/assets/js/search/ninja-keys.min.js?a3446f084dcaecc5f75aa1757d087dcf"></script> <ninja-keys hidebreadcrumbs noautoloadmdicons placeholder="Type to start searching"></ninja-keys> <script src="/assets/js/search-setup.js?6c304f7b1992d4b60f7a07956e52f04a"></script> <script src="/assets/js/search-data.js"></script> <script src="/assets/js/shortcut-key.js?6f508d74becd347268a7f822bca7309d"></script> </body> </html>